Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Lipoprotein (a) as a Biomarker for Cardiovascular Diseases and Potential New Therapies to Mitigate Risk

Author(s): Debabrata Mukherjee* and Steven E Nissen

Volume 22, Issue 3, 2024

Published on: 20 December, 2023

Page: [171 - 179] Pages: 9

DOI: 10.2174/0115701611267835231210054909

Price: $65

Abstract

Background: Lipoprotein (a) [Lp(a)] is a molecule that induces inflammation of the blood vessels, atherogenesis, valvular calcification, and thrombosis.

Methods: We review the available evidence that suggests that high Lp(a) levels are associated with a persisting risk for atherosclerotic cardiovascular diseases despite optimization of established risk factors, including low-density lipoprotein cholesterol (LDL-C) levels.

Observations: Approximately a quarter of the world population have Lp(a) levels of >50 mg/dL (125 nmol/L), a level associated with elevated cardiovascular risk. Lifestyle modification, statins, and ezetimibe do not effectively lower Lp(a) levels, while proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors and niacin only lower Lp(a) levels modestly. We describe clinical studies suggesting that gene silencing therapeutics, such as small interfering RNA (siRNA) and antisense oligonucleotide targeting Lp(a), offer a targeted approach with the potential for safe and robust Lp(a)- lowering with only a few doses (3-4) per year. Prospective randomized phase 3 studies are ongoing to validate safety, effectiveness in improving hard clinical outcomes, and tolerability to assess these therapies.

Conclusion: Several emerging treatments with robust Lp(a)-lowering effects may significantly lower atherosclerotic cardiovascular risk.

« Previous Next »
Graphical Abstract

[1]
Duarte Lau F, Giugliano RP. Lipoprotein(a) and its significance in cardiovascular disease. JAMA Cardiol 2022; 7(7): 760-9.
[http://dx.doi.org/10.1001/jamacardio.2022.0987] [PMID: 35583875]
[2]
Maranhão RC, Carvalho PO, Strunz CC, Pileggi F. Lipoprotein (a): Structure, pathophysiology and clinical implications. Arq Bras Cardiol 2014; 103(1): 76-84.
[http://dx.doi.org/10.5935/abc.20140101] [PMID: 25120086]
[3]
Saleheen D, Haycock PC, Zhao W, et al. Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: A mendelian randomisation analysis. Lancet Diabetes Endocrinol 2017; 5(7): 524-33.
[http://dx.doi.org/10.1016/S2213-8587(17)30088-8] [PMID: 28408323]
[4]
Tada H, Takamura M, Kawashiri M. Lipoprotein(a) as an old and new causal risk factor of atherosclerotic cardiovascular disease. J Atheroscler Thromb 2019; 26(7): 583-91.
[http://dx.doi.org/10.5551/jat.RV17034] [PMID: 31061262]
[5]
Coassin S, Erhart G, Weissensteiner H, et al. A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction. Eur Heart J 2017; 38(23): 1823-31.
[http://dx.doi.org/10.1093/eurheartj/ehx174] [PMID: 28444229]
[6]
Langsted A, Nordestgaard BG, Kamstrup PR. Elevated lipoprotein(a) and risk of ischemic stroke. J Am Coll Cardiol 2019; 74(1): 54-66.
[http://dx.doi.org/10.1016/j.jacc.2019.03.524] [PMID: 31272552]
[7]
Arora P, Kalra R, Callas PW, et al. Lipoprotein(a) and risk of ischemic stroke in the REGARDS study. Arterioscler Thromb Vasc Biol 2019; 39(4): 810-8.
[http://dx.doi.org/10.1161/ATVBAHA.118.311857] [PMID: 30786745]
[8]
Fu H, Zhang D, Zhu R, et al. Association between lipoprotein(a) concentration and the risk of stroke in the Chinese Han population: A retrospective case-control study. Ann Transl Med 2020; 8(5): 212.
[http://dx.doi.org/10.21037/atm.2020.01.38] [PMID: 32309359]
[9]
Aronis KN, Zhao D, Hoogeveen RC, et al. Associations of lipoprotein(a) levels with incident atrial fibrillation and ischemic stroke: The ARIC (Atherosclerosis Risk in Communities) study. J Am Heart Assoc 2017; 6(12): e007372.
[http://dx.doi.org/10.1161/JAHA.117.007372] [PMID: 29246963]
[10]
Pan Y, Li H, Wang Y, Meng X, Wang Y. Causal effect of Lp(a) [lipoprotein(a)] level on ischemic stroke and alzheimer disease. Stroke 2019; 50(12): 3532-9.
[http://dx.doi.org/10.1161/STROKEAHA.119.026872] [PMID: 31597550]
[11]
Kosmas CE, Silverio D, Sourlas A, et al. Role of lipoprotein (a) in peripheral arterial disease. Ann Transl Med 2019; 7(S6) (Suppl. 6): S242.
[http://dx.doi.org/10.21037/atm.2019.08.77] [PMID: 31656821]
[12]
Golledge J, Rowbotham S, Velu R, et al. Association of serum lipoprotein (a) with the requirement for a peripheral artery operation and the incidence of major adverse cardiovascular events in people with peripheral artery disease. J Am Heart Assoc 2020; 9(6): e015355.
[http://dx.doi.org/10.1161/JAHA.119.015355] [PMID: 32172653]
[13]
Madsen CM, Kamstrup PR, Langsted A, Varbo A, Nordestgaard BG. Lipoprotein(a)-lowering by 50 mg/dL (105 nmol/L) may be needed to reduce cardiovascular disease 20% in secondary prevention. Arterioscler Thromb Vasc Biol 2020; 40(1): 255-66.
[http://dx.doi.org/10.1161/ATVBAHA.119.312951] [PMID: 31578080]
[14]
Liu T, Yoon WS, Lee SR. Recent updates of lipoprotein(a) and cardiovascular disease. Chonnam Med J 2021; 57(1): 36-43.
[http://dx.doi.org/10.4068/cmj.2021.57.1.36] [PMID: 33537217]
[15]
Zheng KH, Tsimikas S, Pawade T, et al. Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. J Am Coll Cardiol 2019; 73(17): 2150-62.
[http://dx.doi.org/10.1016/j.jacc.2019.01.070] [PMID: 31047003]
[16]
Vassiliou VS, Flynn PD, Raphael CE, et al. Lipoprotein(a) in patients with aortic stenosis: Insights from cardiovascular magnetic resonance. PLoS One 2017; 12(7): e0181077.
[http://dx.doi.org/10.1371/journal.pone.0181077] [PMID: 28704465]
[17]
Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013; 368(6): 503-12.
[http://dx.doi.org/10.1056/NEJMoa1109034] [PMID: 23388002]
[18]
Patel AP, Wang M, Pirruccello JP, et al. Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: New insights from a large national biobank. Arterioscler Thromb Vasc Biol 2021; 41: 465-74.
[PMID: 33115266]
[19]
Jawi MM, Frohlich J, Chan SY. Lipoprotein(a) the Insurgent: A new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule. J Lipids 2020; 2020: 1-26.
[http://dx.doi.org/10.1155/2020/3491764] [PMID: 32099678]
[20]
Nissen SE, Wolski K, Cho L, et al. Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease. Open Heart 2022; 9(2): e002060.
[http://dx.doi.org/10.1136/openhrt-2022-002060] [PMID: 36252994]
[21]
Mehta A, Jain V, Saeed A, et al. Lipoprotein(a) and ethnicities. Atherosclerosis 2022; 349: 42-52.
[http://dx.doi.org/10.1016/j.atherosclerosis.2022.04.005] [PMID: 35606075]
[22]
Enkhmaa B, Anuurad E, Zhang W, Berglund L. Significant associations between lipoprotein(a) and corrected apolipoprotein B-100 levels in African–Americans. Atherosclerosis 2014; 235(1): 223-9.
[http://dx.doi.org/10.1016/j.atherosclerosis.2014.04.035] [PMID: 24859635]
[23]
Zekavat SM, Ruotsalainen S, Handsaker RE, et al. Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries. Nat Commun 2018; 9(1): 2606.
[http://dx.doi.org/10.1038/s41467-018-04668-w] [PMID: 29973585]
[24]
Paré G, Çaku A, McQueen M, et al. Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups. Circulation 2019; 139(12): 1472-82.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.034311] [PMID: 30667276]
[25]
Hackler E III, Lew J, Gore MO, et al. Racial differences in cardiovascular biomarkers in the general population. J Am Heart Assoc 2019; 8(18): e012729.
[http://dx.doi.org/10.1161/JAHA.119.012729] [PMID: 31514563]
[26]
Berg K. A new serum type system in man—the L p system. Acta Pathol Microbiol Scand 1963; 59(3): 369-82.
[http://dx.doi.org/10.1111/j.1699-0463.1963.tb01808.x] [PMID: 14064818]
[27]
McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330(6144): 132-7.
[http://dx.doi.org/10.1038/330132a0] [PMID: 3670400]
[28]
Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res 2008; 49(10): 2230-9.
[http://dx.doi.org/10.1194/jlr.M800174-JLR200] [PMID: 18594118]
[29]
Tsimikas S. A test in context: Lipoprotein(a). J Am Coll Cardiol 2017; 69(6): 692-711.
[http://dx.doi.org/10.1016/j.jacc.2016.11.042] [PMID: 28183512]
[30]
Miksenas H, Januzzi JL Jr, Natarajan P. Lipoprotein(a) and cardiovascular diseases. JAMA 2021; 326(4): 352-3.
[http://dx.doi.org/10.1001/jama.2021.3632] [PMID: 34236417]
[31]
Steinberg D, Witztum JL. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30(12): 2311-6.
[http://dx.doi.org/10.1161/ATVBAHA.108.179697] [PMID: 21084697]
[32]
Que X, Hung MY, Yeang C, et al. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature 2018; 558(7709): 301-6.
[http://dx.doi.org/10.1038/s41586-018-0198-8] [PMID: 29875409]
[33]
Spence JD, Koschinsky M. Mechanisms of lipoprotein(a) pathogenicity: Prothrombotic, proatherosclerotic, or both? Arterioscler Thromb Vasc Biol 2012; 32(7): 1550-1.
[http://dx.doi.org/10.1161/ATVBAHA.112.251306] [PMID: 22699275]
[34]
Peng J, Liu MM, Liu HH, et al. Lipoprotein (a)-mediated vascular calcification: Population-based and in vitro studies. Metabolism 2022; 127: 154960.
[http://dx.doi.org/10.1016/j.metabol.2021.154960] [PMID: 34954251]
[35]
Kamstrup PR, Benn M, Tybjærg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: The copenhagen city heart study. Circulation 2008; 117(2): 176-84.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.107.715698] [PMID: 18086931]
[36]
Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302(4): 412-23.
[http://dx.doi.org/10.1001/jama.2009.1063] [PMID: 19622820]
[37]
Waldeyer C, Makarova N, Zeller T, et al. Lipoprotein(a) and the risk of cardiovascular disease in the European population: Results from the BiomarCaRE consortium. Eur Heart J 2017; 38(32): 2490-8.
[http://dx.doi.org/10.1093/eurheartj/ehx166] [PMID: 28449027]
[38]
Willeit P, Kiechl S, Kronenberg F, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): Prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol 2014; 64(9): 851-60.
[http://dx.doi.org/10.1016/j.jacc.2014.03.061] [PMID: 25169167]
[39]
Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301(22): 2331-9.
[http://dx.doi.org/10.1001/jama.2009.801] [PMID: 19509380]
[40]
Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361(26): 2518-28.
[http://dx.doi.org/10.1056/NEJMoa0902604] [PMID: 20032323]
[41]
O’Donoghue ML, Morrow DA, Tsimikas S, et al. Lipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol 2014; 63(6): 520-7.
[http://dx.doi.org/10.1016/j.jacc.2013.09.042] [PMID: 24161323]
[42]
Konishi H, Miyauchi K, Kasai T, et al. Impact of lipoprotein(a) as residual risk on long-term outcomes in patients after percutaneous coronary intervention. Am J Cardiol 2015; 115(2): 157-60.
[http://dx.doi.org/10.1016/j.amjcard.2014.10.015] [PMID: 25476560]
[43]
Albers JJ, Slee A, O’Brien KD, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes. J Am Coll Cardiol 2013; 62(17): 1575-9.
[http://dx.doi.org/10.1016/j.jacc.2013.06.051] [PMID: 23973688]
[44]
Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: An analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). Circulation 2014; 129(6): 635-42.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.004406] [PMID: 24243886]
[45]
Gurdasani D, Sjouke B, Tsimikas S, et al. Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: The EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol 2012; 32(12): 3058-65.
[http://dx.doi.org/10.1161/ATVBAHA.112.255521] [PMID: 23065826]
[46]
Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: Insights from epidemiology, genetics, and biology. J Lipid Res 2016; 57(11): 1953-75.
[http://dx.doi.org/10.1194/jlr.R071233] [PMID: 27677946]
[47]
Vuorio A, Watts GF, Schneider WJ, Tsimikas S, Kovanen PT. Familial hypercholesterolemia and elevated lipoprotein(a): Double heritable risk and new therapeutic opportunities. J Intern Med 2020; 287(1): 2-18.
[http://dx.doi.org/10.1111/joim.12981] [PMID: 31858669]
[48]
Alonso R, Andres E, Mata N, et al. Lipoprotein(a) levels in familial hypercholesterolemia: An important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol 2014; 63(19): 1982-9.
[http://dx.doi.org/10.1016/j.jacc.2014.01.063] [PMID: 24632281]
[49]
Wei WQ, Li X, Feng Q, et al. LPA variants are associated with residual cardiovascular risk in patients receiving statins. Circulation 2018; 138(17): 1839-49.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.117.031356] [PMID: 29703846]
[50]
Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement. Eur Heart J 2022; 43(39): 3925-46.
[http://dx.doi.org/10.1093/eurheartj/ehac361] [PMID: 36036785]
[51]
Ellis KL, Pérez de Isla L, Alonso R, Fuentes F, Watts GF, Mata P. Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia. J Am Coll Cardiol 2019; 73(9): 1029-39.
[http://dx.doi.org/10.1016/j.jacc.2018.12.037] [PMID: 30846097]
[52]
Holmes DT, Schick BA, Humphries KH, Frohlich J. Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem 2005; 51(11): 2067-73.
[http://dx.doi.org/10.1373/clinchem.2005.055228] [PMID: 16141286]
[53]
Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: A scientific statement from the american heart association. Arterioscler Thromb Vasc Biol 2022; 42(1): e48-60.
[http://dx.doi.org/10.1161/ATV.0000000000000147] [PMID: 34647487]
[54]
Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the national lipid association. J Clin Lipidol 2019; 13(3): 374-92.
[http://dx.doi.org/10.1016/j.jacl.2019.04.010] [PMID: 31147269]
[55]
Cegla J, Neely RDG, France M, et al. HEART UK consensus statement on Lipoprotein(a): A call to action. Atherosclerosis 2019; 291: 62-70.
[http://dx.doi.org/10.1016/j.atherosclerosis.2019.10.011] [PMID: 31704552]
[56]
Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372(16): 1489-99.
[http://dx.doi.org/10.1056/NEJMoa1501031] [PMID: 25773378]
[57]
Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients. BMJ 2014; 349(jul18 2): g4379.
[http://dx.doi.org/10.1136/bmj.g4379] [PMID: 25038074]
[58]
Toth PP, Jones SR, Monsalvo ML, Elliott-Davey M, López JAG, Banach M. Effect of evolocumab on non‐high‐density lipoprotein cholesterol, apolipoprotein b, and lipoprotein(a): A pooled analysis of phase 2 and phase 3 studies. J Am Heart Assoc 2020; 9(5): e014129.
[http://dx.doi.org/10.1161/JAHA.119.014129] [PMID: 32114889]
[59]
Bittner VA, Szarek M, Aylward PE, et al. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol 2020; 75(2): 133-44.
[http://dx.doi.org/10.1016/j.jacc.2019.10.057] [PMID: 31948641]
[60]
Awad K, Mikhailidis DP, Katsiki N, Muntner P, Banach M. Effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia: A systematic review and meta-analysis of randomized controlled trials. Drugs 2018; 78(4): 453-62.
[http://dx.doi.org/10.1007/s40265-018-0870-1] [PMID: 29396832]
[61]
De Marchis GM, Dittrich TD, Malik R, et al. Genetic proxies for PCSK9 inhibition associate with lipoprotein(a): Effects on coronary artery disease and ischemic stroke. Atherosclerosis 2022; 361: 41-6.
[http://dx.doi.org/10.1016/j.atherosclerosis.2022.09.007] [PMID: 36244797]
[62]
O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation 2019; 139(12): 1483-92.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.037184] [PMID: 30586750]
[63]
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376(18): 1713-22.
[http://dx.doi.org/10.1056/NEJMoa1615664] [PMID: 28304224]
[64]
Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA-targeted therapeutics. Cell Metab 2018; 27(4): 714-39.
[http://dx.doi.org/10.1016/j.cmet.2018.03.004] [PMID: 29617640]
[65]
Tsimikas S. Antisense oligonucleotide therapy to treat elevated lipoprotein(a)Contemporary Cardiology Humana. Cham: Humana 2023.
[http://dx.doi.org/10.1007/978-3-031-24575-6_22]
[66]
Katzmann JL, Packard CJ, Chapman MJ, Katzmann I, Laufs U. Targeting RNA with antisense oligonucleotides and small interfering RNA: JACC state-of-the-art review. J Am Coll Cardiol 2020; 76(5): 563-79.
[http://dx.doi.org/10.1016/j.jacc.2020.05.070] [PMID: 32731935]
[67]
Lippi G, Favaloro EJ, Sanchis-Gomar F. Antisense lipoprotein[a] therapy: State-of-the-art and future perspectives. Eur J Intern Med 2020; 76: 8-13.
[http://dx.doi.org/10.1016/j.ejim.2020.04.036] [PMID: 32336611]
[68]
Shen X, Corey DR. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res 2018; 46(4): 1584-600.
[http://dx.doi.org/10.1093/nar/gkx1239] [PMID: 29240946]
[69]
Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): Two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 2016; 388(10057): 2239-53.
[http://dx.doi.org/10.1016/S0140-6736(16)31009-1] [PMID: 27665230]
[70]
Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med 2020; 382(3): 244-55.
[http://dx.doi.org/10.1056/NEJMoa1905239] [PMID: 31893580]
[71]
Yeang C, Karwatowska-Prokopczuk E, Su F, et al. Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol. J Am Coll Cardiol 2022; 79(11): 1035-46.
[http://dx.doi.org/10.1016/j.jacc.2021.12.032] [PMID: 35300814]
[72]
Plakogiannis R, Sorbera M, Fischetti B, Chen M. The role of antisense therapies targeting lipoprotein(a). J Cardiovasc Pharmacol 2021; 78(1): e5-e11.
[http://dx.doi.org/10.1097/FJC.0000000000001045] [PMID: 34232223]
[73]
Koren MJ, Moriarty PM, Baum SJ, et al. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nat Med 2022; 28(1): 96-103.
[http://dx.doi.org/10.1038/s41591-021-01634-w] [PMID: 35027752]
[74]
O’Donoghue MLG, G López JA, Knusel B, et al. Study design and rationale for the olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE). Am Heart J 2022; 251: 61-9.
[http://dx.doi.org/10.1016/j.ahj.2022.05.004] [PMID: 35588897]
[75]
O’Donoghue ML, Rosenson RS, Gencer B, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med 2022; 387(20): 1855-64.
[http://dx.doi.org/10.1056/NEJMoa2211023] [PMID: 36342163]
[76]
Nissen SE, Wolski K, Balog C, et al. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. JAMA 2022; 327(17): 1679-87.
[http://dx.doi.org/10.1001/jama.2022.5050] [PMID: 35368052]
[77]
Nicholls SJ, Nissen SE, Fleming C, et al. Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation. JAMA 2023; 330(11): 1042-53.
[http://dx.doi.org/10.1001/jama.2023.16503] [PMID: 37638695]
[78]
Swerdlow DI, Rider DA, Yavari A, Wikström Lindholm M, Campion GV, Nissen SE. Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics. Cardiovasc Res 2022; 118(5): 1218-31.
[http://dx.doi.org/10.1093/cvr/cvab100] [PMID: 33769464]
[79]
Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 380(9841): 565-71.
[http://dx.doi.org/10.1016/S0140-6736(12)61190-8] [PMID: 22883507]
[80]
Swerdlow DI, Preiss D. Genetic insights into statin-associated diabetes risk. Curr Opin Lipidol 2016; 27(2): 125-30.
[http://dx.doi.org/10.1097/MOL.0000000000000272] [PMID: 26959703]
[81]
Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992; 90(1): 52-60.
[http://dx.doi.org/10.1172/JCI115855] [PMID: 1386087]
[82]
Swerdlow DI, Hingorani AD, Humphries SE. Genetic risk factors and Mendelian randomization in cardiovascular disease. Curr Cardiol Rep 2015; 17(5): 33.
[http://dx.doi.org/10.1007/s11886-015-0584-x] [PMID: 25894797]
[83]
Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. J Lipid Res 2016; 57(4): 526-37.
[http://dx.doi.org/10.1194/jlr.R061648] [PMID: 26637278]
[84]
Diederiks NM, van der Burgt YEM, Ruhaak LR, Cobbaert CM. Developing an SI-traceable Lp(a) reference measurement system: A pilgrimage to selective and accurate apo(a) quantification. Crit Rev Clin Lab Sci 2023; 60(7): 483-501.
[http://dx.doi.org/10.1080/10408363.2023.2199353] [PMID: 37128734]
[85]
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111-88.
[http://dx.doi.org/10.1093/eurheartj/ehz455] [PMID: 31504418]
[86]
Langsted A, Nordestgaard BG. Value of genetic testing for lipoprotein(a) variants. Circ Genom Precis Med 2022; 15(2): e003737.
[http://dx.doi.org/10.1161/CIRCGEN.122.003737] [PMID: 35311528]
[87]
Paquette M, Bernard S, Thanassoulis G, Baass A. LPA genotype is associated with premature cardiovascular disease in familial hypercholesterolemia. J Clin Lipidol 2019; 13(4): 627-633.e1.
[http://dx.doi.org/10.1016/j.jacl.2019.04.006] [PMID: 31103339]
[88]
Kronenberg F. Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region. Clin Res Cardiol Suppl 2019; 14(S1) (Suppl. 1): 5-12.
[http://dx.doi.org/10.1007/s11789-019-00093-5] [PMID: 30859385]
[89]
Duncan MS, Vasan RS, Xanthakis V. Trajectories of blood lipid concentrations over the adult life course and risk of cardiovascular disease and all‐cause mortality: Observations from the framingham study over 35 years. J Am Heart Assoc 2019; 8(11): e011433.
[http://dx.doi.org/10.1161/JAHA.118.011433] [PMID: 31137992]
[90]
McNeal CJ. Lipoprotein(a): Its relevance to the pediatric population. J Clin Lipidol 2015; 9(5) (Suppl.): S57-66.
[http://dx.doi.org/10.1016/j.jacl.2015.07.006] [PMID: 26343213]
[91]
Liu HH, Cao YX, Jin JL, et al. Association of lipoprotein(a) levels with recurrent events in patients with coronary artery disease. Heart 2020; 106(16): 1228-35.
[http://dx.doi.org/10.1136/heartjnl-2020-316586] [PMID: 32381650]
[92]
Schwartz GG, Ballantyne CM, Barter PJ, et al. Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome. JAMA Cardiol 2018; 3(2): 164-8.
[http://dx.doi.org/10.1001/jamacardio.2017.3833] [PMID: 29071331]
[93]
Larsson SC, Gill D, Mason AM, et al. Lipoprotein(a) in alzheimer, atherosclerotic, cerebrovascular, thrombotic, and valvular disease. Circulation 2020; 141(22): 1826-8.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.120.045826] [PMID: 32479194]
[94]
Burgess S, Ference BA, Staley JR, et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies. JAMA Cardiol 2018; 3(7): 619-27.
[http://dx.doi.org/10.1001/jamacardio.2018.1470] [PMID: 29926099]
[95]
Willeit P, Ridker PM, Nestel PJ, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet 2018; 392(10155): 1311-20.
[http://dx.doi.org/10.1016/S0140-6736(18)31652-0] [PMID: 30293769]
[96]
Miname MH, Rocha VZ, Santos RD. The role of RNA-targeted therapeutics to reduce ASCVD risk: What have we learned recently? Curr Atheroscler Rep 2021; 23(8): 40.
[http://dx.doi.org/10.1007/s11883-021-00936-1] [PMID: 34146170]
[97]
Sosnowska B, Surma S, Banach M. Targeted treatment against lipoprotein (a): The coming breakthrough in lipid lowering therapy. Pharmaceuticals 2022; 15(12): 1573.
[http://dx.doi.org/10.3390/ph15121573] [PMID: 36559024]
[98]
Parthymos I, Kostapanos MS, Mikhailidis DP, Florentin M. Lipoprotein (a) as a treatment target for cardiovascular disease prevention and related therapeutic strategies: A critical overview. Eur J Prev Cardiol 2022; 29(5): 739-55.
[http://dx.doi.org/10.1093/eurjpc/zwab052] [PMID: 34389859]
[99]
Berg K, Dahlén G, Christophersen B, Cook T, Kjekshus J, Pedersen T. Lp(a) lipoprotein level predicts survival and major coronary events in the scandinavian simvastatin survival study. Clin Genet 1997; 52(5): 254-61.
[http://dx.doi.org/10.1111/j.1399-0004.1997.tb04342.x] [PMID: 9520115]
[100]
Lamina C, Kronenberg F. Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes. JAMA Cardiol 2019; 4(6): 575-9.
[http://dx.doi.org/10.1001/jamacardio.2019.1041] [PMID: 31017618]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy